Pafuramidine Explained

Pafuramidine (formulated as the maleic acid salt pafuramidine maleate) is an experimental drug for the treatment of pneumocystis pneumonia (PCP). In 2006, pafuramidine was given orphan drug status by the US Food and Drug Administration for PCP in patients with HIV/AIDS.[1] Preliminary clinical trials indicated that pafuramide was effective against pneumocystis pneumonia and had the potential for fewer side effects than the standard treatment with trimethoprim/sulfamethoxazole (TMP-SMX).[2]

Pafuramidine also reached Phase III clinical trials for the treatment of first stage African sleeping sickness, but development was halted in 2008 over concerns about kidney toxicity.[3] [4]

Notes and References

  1. Web site: US FDA Grants Immtech's Oral Drug Candidate Pafuramidine (DB289) Orphan Drug Status for Treatment of PCP . . November 21, 2006.
  2. Chen D, Marsh R, Aberg JA . Pafuramidine for Pneumocystis jiroveci pneumonia in HIV-infected individuals . Expert Review of Anti-Infective Therapy . 5 . 6 . 921–928 . December 2007 . 18039076 . 10.1586/14787210.5.6.921 . 22249374 .
  3. Web site: Pafuramidine maleate (DB289) . Swiss Tropical and Public Health Initiative.
  4. Harrill AH, Desmet KD, Wolf KK, Bridges AS, Eaddy JS, Kurtz CL, Hall JE, Paine MF, Tidwell RR, Watkins PB . 6 . A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models . Toxicological Sciences . 130 . 2 . 416–426 . December 2012 . 22940726 . 3498743 . 10.1093/toxsci/kfs238 .

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Pafuramidine".

Except where otherwise indicated, Everything.Explained.Today is © Copyright 2009-2024, A B Cryer, All Rights Reserved. Cookie policy.